MIRA PHARMACEUTICALS, INC.

# MIRA Pharmaceuticals, Inc. (MIRA)

Based in Miami, Florida, MIRA Pharmaceuticals is a pre-clinical-stage pharmaceutical development company focused on neuroscience therapeutics. The company operates two primary drug development programs targeting neurologic and neuropsychiatric disorders. Ketamir-2, a patent-pending oral ketamine analog, is under investigation for treating treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder, with the compound designed to deliver ultra-rapid antidepressant effects. The company holds exclusive U.S., Canadian, and Mexican rights to this asset. MIRA's second program, MIRA-55, is an oral pharmaceutical marijuana formulation in development for anxiety and cognitive decline associated with early-stage dementia.

As an early-stage development company, MIRA generates no material revenue and remains in the pre-clinical phase of drug development. The company was incorporated in Florida in 2020 and is listed on Nasdaq under the ticker MIRA. With a market capitalization of approximately $0.1 billion, the company maintains a small operational footprint consistent with its stage of development and focus on clinical research and regulatory pathway advancement.